Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)

Original article
Hofer S, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Pflugshaupt T, Eggenberger N, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching HG, Wolpert F, Roth P, Weller M
Swiss Med Wkly. 2021;151:w20501

The management of brain tumour patients who would like to resume driving is complex, and needs multidisciplinary input and a consensus among treating physicians. The Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM) aim to provide guidance on how to assess “fitness-to-drive” of glioblastoma patients and to harmonise the relevant procedures in Switzerland.

Impact of the new TNM Staging System (8th edition) on oral tongue cancers

Original article
Ammann Y, Beutner U, Vital DG, Morand G, Broglie Daeppen MA, Born D, Stoeckli SJ, Huber GF
Swiss Med Wkly. 2021;151:w20493

For tumours of the oral tongue, the most recent 8th edition of the AJCC/UICC staging system has introduced depth of infiltration (DOI) as a novel parameter. The authors of this study investigated its impact regarding this risk stratification compared with the preceding 7th edition. The recent TNM 8th edition provides a more accurate prediction of overall and disease-specific survival for this subgroup of patients. Hence, a more aggressive treatment should be considered for patients re-staged to pT3 due to depth of infiltration.

ASA score and procedure type predict complications and costs in maxillofacial reconstructive surgery: a retrospective study using a hospital administrative database

Original article
Mehra T, Schönegg D, Ebner J, Moos RM, Schumann P, Gander T, Essig H, Lanzer M
Swiss Med Wkly. 2021;151:w20497

The ASA score allows a reliable preoperative assessment of patient outcomes and financial burden in maxillofacial reconstructive flap surgery. The type of flap reconstruction significantly influences complications and ultimately total costs. The current reimbursement system via diagnosis-related groups (DRGs) does not take sufficient account of this fact. Adaptations are therefore needed to prevent misplaced incentives to the detriment of patients.

Role of myeloid-derived suppressor cells in hormone-dependent cancers

Review article: Biomedical intelligence
Mukherjee S, Elia AR, Calcinotto A
Swiss Med Wkly. 2021;151:w20483

The main feature of myeloid-derived suppressor cells (MDSCs) is their ability to suppress T-cell activation and function, which leads to immunosuppressive activity in the tumour microenvironment. Higher numbers of circulating and tumour-infiltrating MDSCs have been observed in a large number of patients with various types of tumour, and are linked to poor prognosis, especially in hormone-driven tumours. Recently, it has been demonstrated that the recruitment of MDSCs in prostate cancer confers resistance to canonical endocrine therapies, opening a new approach to the treatment of hormone-driven cancer patients.

Trends of incidence, mortality and survival for chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland between 1997 and 2016: a population-based study

Original article
Andres M, Feller A, Arndt V, The NICER Working Group
Swiss Med Wkly. 2021;151:w20463

During the last 20 years, treatment for chronic lymphocytic leukaemia and small lymphocytic lymphoma has advanced, with improved clinical outcomes in randomised controlled trials, but no data have been published from Switzerland to assess effectiveness of recent healthcare advances in CLL/SLL on a population-based level.

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study

Original article
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT
Swiss Med Wkly. 2021;151:w20464

International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer with bone metastases. Whereas denosumab has never been studied in this patient population, zoledronic acid has been shown to be ineffective in decreasing the risk for skeletal-related events. This study estimates the prevalence and economic consequences of real-world use of bone-targeted agents for mCSPC patients in Switzerland.

Multimodal treatment strategies for colorectal liver metastases

Review article: Biomedical intelligence
Birrer DL, Tschuor C, Reiner C, Fritsch R, Pfammatter T, Garcia Schüler H, Pavic M, De Oliveira M, Petrowsky H, Dutkowski P, Oberkofler C, Clavien PA
Swiss Med Wkly. 2021;151:w20390

The optimal treatment of patients with colorectal liver metastases requires the timely association of various strategies, and all cases must be discussed at multidisciplinary team conferences. While colorectal liver metastases was a uniformly lethal condition a few decades ago, it has become amenable to curative therapies, with excellent quality of life in many scenarios. This review reports on up-to-date treatment modalities and their combinations in the treatment algorithm of colorectal liver metastases.

Gestational trophoblastic disease in Switzerland: retrospective study of the impact of a regional reference centre

Original article
Fehlmann A, Benkortbi K, Rosseel G, Meyer-Hamme U, Tille JC, Sloan-Bena F, Paoloni-Giacobino A, Rougemont AL, Bodmer A, Botsikas D, Mathevet P, Petignat P, Undurraga Malinverno M
Swiss Med Wkly. 2021;151:w20406

The European Society of Medical Oncology recommends that countries should have reference centres to provide adequate diagnosis and treatment of gestational trophoblastic disease. This study reflects the activity of the Swiss trophoblastic disease centre from the French-speaking part of Switzerland created in 2009, and its role as local and national reference centre, in terms of global health, for women with gestational trophoblastic disease.

Lymphovascular invasion is an independent prognostic factor for survival in pathologically proven N2 non-small cell lung cancer

Original article
Guglielmetti LC, Schneiter D, Hillinger S, Opitz I, Caviezel C, Weder W, Inci I
Swiss Med Wkly. 2021;151:w20385

Lymphovascular invasion was identified as the only independent prognostic factor for 5-year overall survival and recurrence-free survival in this pathologically proven N2 NSCLC cohort when controlled for adjuvant therapy. This study extends the current evidence of an adverse prognostic effect of lymphovascular invasion on a stage III population, confirms the adverse prognostic effect of lymphovascular invasion detected by immunohistochemistry, and thereby reveals another subgroup within the pN2 population with worse prognosis regarding 5-year overall survival and recurrence-free survival.

37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich

Original article
Wanner M, Matthes KL, Karavasiloglou N, Limam M, Korol D, Rohrmann S
Swiss Med Wkly. 2020;150:w20388

The Cancer Registry Zurich, Zug, Schaffhausen and Schwyz is one of the oldest cancer registries in Switzerland, first registering tumours in 1980 for the canton of Zurich. The aim of this study was to analyse trends in incidence and mortality for the most common types of cancer in the canton of Zurich from 1981 to 2017.

Verpassen Sie keinen Artikel!

close